SNX-5422 plus ibrutinib

DRUG2 trials

Sponsors

Esanex Inc.

Conditions

Cancer

Phase 1

Safety and Activity of SNX-5422 Plus Ibrutinib in CLL

WithdrawnNCT02914327

Esanex Inc.Cancer

Start: 2017-02-02End: 2018-07-01Updated: 2018-07-30

Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL

TerminatedNCT02973399

Esanex Inc.Cancer

Start: 2017-02-07End: 2019-02-04Updated: 2019-02-22

Related Papers

Abstract 1964: Preclinical efficacy of the HSP90 inhibitor SNX-5422 in targeting C481S mutant BTK and ibrutinib resistant CLL

Cancer Research2018-07-01